Sara J. Buhrlage, Ph.D.

Affiliations: 
2015 Harvard Medical School/Dana-Farber Cancer Institute, Boston, MA, United States 
Area:
Chemical biology
Google:
"Sara Buhrlage"
Mean distance: 8.57
 
SNBCP

Parents

Sign in to add mentor
Anna K. Mapp grad student 2008 University of Michigan
 (Small molecule transcriptional activation domains.)
Nathanael Gray research scientist 2010-2015 Harvard Medical School/Dana-Farber Cancer Institute
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Koduri V, Duplaquet L, Lampson BL, et al. (2021) Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances. 7
Donovan KA, Ferguson FM, Bushman JW, et al. (2020) Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development. Cell
Weisberg E, Parent A, Yang PL, et al. (2020) Repurposing of Kinase Inhibitors for Treatment of COVID-19. Pharmaceutical Research. 37: 167
Schauer NJ, Liu X, Magin RS, et al. (2020) Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism. Scientific Reports. 10: 5324
Weisberg E, Meng C, Case A, et al. (2020) Correction: Evaluation of ERK as a therapeutic target in acute myelogenous leukemia. Leukemia
Yang J, Meng C, Weisberg E, et al. (2020) Inhibition of the deubiquitinase USP10 induces degradation of SYK. British Journal of Cancer
Munshi M, Liu X, Chen JG, et al. (2020) SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. Blood Cancer Journal. 10: 12
Weisberg E, Meng C, Case AE, et al. (2020) Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia. Journal of Cellular and Molecular Medicine
Weisberg E, Meng C, Case AE, et al. (2019) Comparison of effects of midostaurin, crenolanib, quizartinib, gilteritinib, sorafenib and BLU-285 on oncogenic mutants of KIT, CBL and FLT3 in haematological malignancies. British Journal of Haematology
Wang L, Ferrao R, Li Q, et al. (2019) Conformational flexibility and inhibitor binding to unphosphorylated interleukin-1 receptor-associated kinase 4 (IRAK4). The Journal of Biological Chemistry
See more...